Rothschild Capital Partners Llc decreased First Rep Bk San Francisco C (FRC) stake by 38.63% reported in 2016Q4 SEC filing. Rothschild Capital Partners Llc sold 46,245 shares as First Rep Bk San Francisco C (FRC)’s stock rose 12.19%. The Rothschild Capital Partners Llc holds 73,479 shares with $6.77 million value, down from 119,724 last quarter. First Rep Bk San Francisco C now has $13.96B valuation. The stock decreased 0.64% or $0.58 during the last trading session, reaching $90.34. About shares traded. First Republic Bank (NYSE:FRC) has risen 22.53% since August 19, 2016 and is uptrending. It has outperformed by 15.31% the S&P500.
Analysts expect Interpace Diagnostics Group Inc (NASDAQ:IDXG) to report $0.00 EPS on March, 29. The stock decreased 2.99% or $0.07 during the last trading session, reaching $2.27. About shares traded. Interpace Diagnostics Group Inc (NASDAQ:IDXG) has declined 21.72% since August 19, 2016 and is downtrending. It has underperformed by 28.95% the S&P500.
Analysts await First Republic Bank (NYSE:FRC) to report earnings on April, 13. They expect $1.02 earnings per share, up 15.91% or $0.14 from last year’s $0.88 per share. FRC’s profit will be $157.62M for 22.14 P/E if the $1.02 EPS becomes a reality. After $1.03 actual earnings per share reported by First Republic Bank for the previous quarter, Wall Street now forecasts -0.97% negative EPS growth.
Among 14 analysts covering First Republic Bank (NYSE:FRC), 8 have Buy rating, 0 Sell and 6 Hold. Therefore 57% are positive. First Republic Bank had 29 analyst reports since October 6, 2015 according to SRatingsIntel. The firm has “Mkt Perform” rating given on Friday, July 15 by FBR Capital. The firm has “Equal-Weight” rating given on Wednesday, November 16 by Morgan Stanley. The firm has “Outperform” rating by FBR Capital given on Tuesday, December 20. RBC Capital Markets maintained the shares of FRC in report on Friday, March 10 with “Sector Perform” rating. On Friday, October 14 the stock rating was maintained by Wood with “Market Perform”. The stock of First Republic Bank (NYSE:FRC) has “Outperform” rating given on Wednesday, November 11 by Raymond James. BMO Capital Markets maintained the stock with “Hold” rating in Thursday, March 23 report. The firm earned “Buy” rating on Monday, February 22 by HSBC. The rating was maintained by Keefe Bruyette & Woods on Friday, July 15 with “Market Perform”. The stock of First Republic Bank (NYSE:FRC) earned “Buy” rating by Maxim Group on Tuesday, January 17.
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The company has market cap of $10.90 million. The Firm operates through molecular diagnostics segment. It currently has negative earnings. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay.
